Advances in the proteomic discovery of novel therapeutic targets in cancer

References

• Hondermarck H Tastet C El Yazidi-Belkoura I Toillon RA Le Bourhis X Proteomics of breast cancer: the quest for markers and therapeutic targets J Proteome Res 2008 7 4 1403 1411 18311906
   PubMed Web of Science ®Google Scholar
• Fink-Retter A Czerwenka K Gschwantler-Kaulich D Proteomics in mammary cancer research Eur J Gynaecol Oncol 2009 30 6 635 639 20099493
   PubMed Web of Science ®Google Scholar
• Griffith OL Gray JW Omic approaches to preventing or managing metastatic breast cancer Breast Cancer Res 2011 13 6 230 22216753
   PubMed Web of Science ®Google Scholar
• Sharma N Martin A McCabe CJ Mining the proteome: the application of tandem mass spectrometry to endocrine cancer research Endocr Relat Cancer 2012 19 4 R149 R161 22555494
   PubMed Web of Science ®Google Scholar
• Gräntzdörffer I Carl-McGrath S Ebert MP Röcken C Proteomics of pancreatic cancer Pancreas 2008 36 4 329 336 18437077
   PubMed Web of Science ®Google Scholar
• Tonack S Aspinall-O’Dea M Neoptolemos JP Costello E Pancreatic cancer: proteomic approaches to a challenging disease Pancreatology 2009 9 5 567 576 19657212
   PubMed Web of Science ®Google Scholar
• Faça VM Hanash SM In-depth proteomics to define the cell surface and secretome of ovarian cancer cells and processes of protein shedding Cancer Res 2009 69 3 728 730 19155298
   PubMed Web of Science ®Google Scholar
• Hays JL Kim G Giuroiu I Kohn EC Proteomics and ovarian cancer: integrating proteomics information into clinical care J Proteomics 2010 73 10 1864 1872 20561909
   PubMed Web of Science ®Google Scholar
• Callesen AK Mogensen O Jensen AK Reproducibility of mass spectrometry based protein profiles for diagnosis of ovarian cancer across clinical studies: A systematic review J Proteomics 2012 75 10 2758 2772 22366292
   PubMed Web of Science ®Google Scholar
• Barderas R Babel I Casal JI Colorectal cancer proteomics, molecular characterization and biomarker discovery Proteomics Clin Appl 2010 4 2 159 178 21137041
   PubMed Web of Science ®Google Scholar
• McHugh SM O’Donnell J Gillen P Genomic and oncoproteomic advances in detection and treatment of colorectal cancer World J Surg Oncol 2009 7 36 19338662
   PubMed Web of Science ®Google Scholar
• Kalinina J Peng J Ritchie JC Van Meir EG Proteomics of gliomas: initial biomarker discovery and evolution of technology Neuro Oncol 2011 13 9 926 942 21852429
   PubMed Web of Science ®Google Scholar
• Jung CS Unterberg AW Hartmann C Diagnostic markers for glioblastoma Histol Histopathol 2011 26 10 1327 1341 21870336
   PubMed Web of Science ®Google Scholar
• Niclou SP Fack F Rajcevic U Glioma proteomics: status and perspectives J Proteomics 2010 73 10 1823 1838 20332038
   PubMed Web of Science ®Google Scholar
• Cazares LH Troyer DA Wang B Drake RR Semmes OJ MALDI tissue imaging: from biomarker discovery to clinical applications Anal Bioanal Chem 2011 401 1 17 27 21541816
   PubMed Web of Science ®Google Scholar
• Schwamborn K Gaisa NT Henkel C Tissue and serum proteomic profiling for diagnostic and prognostic bladder cancer biomarkers Expert Rev Proteomics 2010 7 6 897 906 21142890
   PubMed Web of Science ®Google Scholar
• Moreira JM Cabezón T Gromova I Tissue proteomics of the human mammary gland: towards an abridged definition of the molecular phenotypes underlying epithelial normalcy Mol Oncol 2010 4 6 539 561 21036680
   PubMed Web of Science ®Google Scholar
• Somasundaram K Nijaguna MB Kumar DM Serum proteomics of glioma: methods and applications Expert Rev Mol Diagn 2009 9 7 695 707 19817554
   PubMed Web of Science ®Google Scholar
• Solassol J Du-Thanh A Maudelonde T Guillot B Serum proteomic profiling reveals potential biomarkers for cutaneous malignant melanoma Int J Biol Markers 2011 26 2 82 87 21607923
   PubMed Web of Science ®Google Scholar
• Fanayan S Hincapie M Hancock WS Using lectins to harvest the plasma/serum glycoproteome Electrophoresis 2012 33 12 1746 1754 22740463
   PubMed Web of Science ®Google Scholar
• Chen ST Pan TL Juan HF Chen TY Lin YS Huang CM Breast tumor microenvironment: proteomics highlights the treatments targeting secretome J Proteome Res 2008 7 4 1379 1387 18290608
   PubMed Web of Science ®Google Scholar
• Xue H Lu B Lai M The cancer secretome: a reservoir of biomarkers J Transl Med 2008 6 52 18796163
   PubMed Web of Science ®Google Scholar
• Stastna M Van Eyk JE Secreted proteins as a fundamental source for biomarker discovery Proteomics 2012 12 4–5 722 735 22247067
   PubMed Web of Science ®Google Scholar
• Harsha HC Pandey A Phosphoproteomics in cancer Mol Oncol 2010 4 6 482 495 20937571
   PubMed Web of Science ®Google Scholar
• Trost M Bridon G Desjardins M Thibault P Subcellular phosphoproteomics Mass Spectrom Rev 2010 29 6 962 990 20931658
   PubMed Web of Science ®Google Scholar
• Ashman K Villar EL Phosphoproteomics and cancer research Clin Transl Oncol 2009 11 6 356 362 19531450
   PubMed Web of Science ®Google Scholar
• Chong PK Lee H Kong JW Loh MC Wong CH Lim YP Phosphoproteomics, oncogenic signaling and cancer research Proteomics 2008 8 21 4370 4382 18814326
   PubMed Web of Science ®Google Scholar
• Li XH Li C Xiao ZQ Proteomics for identifying mechanisms and biomarkers of drug resistance in cancer J Proteomics 2011 74 12 2642 2649 21964283
   PubMed Web of Science ®Google Scholar
• Koomen JM Smalley KS Using quantitative proteomic analysis to understand genotype specific intrinsic drug resistance in melanoma Oncotarget 2011 2 4 329 335 21505227
   PubMedGoogle Scholar
• Hodgkinson VC Eagle GL Drew PJ Lind MJ Cawkwell L Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: current status Cancer Lett 2010 294 1 13 24 20176436
   PubMed Web of Science ®Google Scholar
• Piersma SR Labots M Verheul HM Jiménez CR Strategies for kinome profiling in cancer and potential clinical applications: chemical proteomics and array-based methods Anal Bioanal Chem 2010 397 8 3163 3171 20526883
   PubMed Web of Science ®Google Scholar
• Parikh K Peppelenbosch MP Kinome profiling of clinical cancer specimens Cancer Res 2010 70 7 2575 2578 20332226
   PubMed Web of Science ®Google Scholar
• Hochgräfe F Zhang L O’Toole SA Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells Cancer Res 2010 70 22 9391 9401 20861192
   PubMed Web of Science ®Google Scholar
• Liang S Xu Z Xu X Zhao X Huang C Wei Y Quantitative proteomics for cancer biomarker discovery Comb Chem High Throughput Screen 2012 15 3 221 231 22221055
   PubMed Web of Science ®Google Scholar
• Lin LL Huang HC Juan HF Discovery of biomarkers for gastric cancer: a proteomics approach J Proteomics 2012 75 11 3081 3097 22498886
   PubMed Web of Science ®Google Scholar
• Leth-Larsen R Lund RR Ditzel HJ Plasma membrane proteomics and its application in clinical cancer biomarker discovery Mol Cell Proteomics 2010 9 7 1369 1382 20382631
   PubMed Web of Science ®Google Scholar
• Drake RR Cazares LH Jones EE Fuller TW Semmes OJ Laronga C Challenges to developing proteomic-based breast cancer diagnostics OMICS 2011 15 5 251 259 21332380
   PubMed Web of Science ®Google Scholar
• Abramovitz M Leyland-Jones B Application of array-based genomic and epigenomic technologies to unraveling the heterogeneous nature of breast tumors: on the road to individualized treatment Cancer Genomics Proteomics 2007 4 3 135 145 17878517
   PubMedGoogle Scholar
• Lam SW Jimenez CR Boven E Breast cancer classification by proteomic technologies: Current state of knowledge Cancer Treat Rev Epub 7 23 2013 pii S0305-7372(13)00129-00121
   Web of Science ®Google Scholar
• Ohtsuki S Uchida Y Kubo Y Terasaki T Quantitative targeted absolute proteomics-based ADME research as a new path to drug discovery and development: methodology, advantages, strategy, and prospects J Pharm Sci 2011 100 9 3547 3559 21560129
   PubMed Web of Science ®Google Scholar
• Schirle M Bantscheff M Kuster B Mass spectrometry-based proteomics in preclinical drug discovery Chem Biol 2012 19 1 72 84 22284356
   PubMed Web of Science ®Google Scholar
• Rajcevic U Niclou SP Jimenez CR Proteomics strategies for target identification and biomarker discovery in cancer Front Biosci (Landmark Ed) 2009 14 3292 3303 19273274
   PubMed Web of Science ®Google Scholar
• Mikami T Aoki M Kimura T The application of mass spectrometry to proteomics and metabolomics in biomarker discovery and drug development Curr Mol Pharmacol 2012 5 2 301 316 22122469
   PubMedGoogle Scholar
• Creighton CJ Fu X Hennessy BT Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer Breast Cancer Res 2010 12 3 R40 20569503
   PubMed Web of Science ®Google Scholar
• Arsenault R Griebel P Napper S Peptide arrays for kinome analysis: new opportunities and remaining challenges Proteomics 2011 11 24 4595 4609 22002874
   PubMed Web of Science ®Google Scholar
• Beyer M Block I König K A novel combinatorial approach to high-density peptide arrays Methods Mol Biol 2009 570 309 316 19649602
   PubMedGoogle Scholar
• Sheehan KM Calvert VS Kay EW Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma Mol Cell Proteomics 2005 4 4 346 355 15671044
   PubMed Web of Science ®Google Scholar
• Wilson B Liotta LA Petricoin E Monitoring proteins and protein networks using reverse phase protein arrays Dis Markers 2010 28 4 225 232 20534907
   PubMed Web of Science ®Google Scholar
• Voshol H Ehrat M Traenkle J Bertrand E van Oostrum J Antibody-based proteomics: analysis of signaling networks using reverse protein arrays FEBS J 2009 276 23 6871 6879 19860827
   PubMed Web of Science ®Google Scholar
• Sereni MI Pierobon M Angioli R Petricoin EF Frederick MJ Reverse phase protein microarrays and their utility in drug development Methods Mol Biol 2013 986 187 214 23436414
   PubMedGoogle Scholar
• Patel VJ Thalassinos K Slade SE A comparison of labeling and label-free mass spectrometry-based proteomics approaches J Proteome Res 2009 8 7 3752 3759 19435289
   PubMed Web of Science ®Google Scholar
• Bantscheff M Schirle M Sweetman G Rick J Kuster B Quantitative mass spectrometry in proteomics: a critical review Anal Bioanal Chem 2007 389 4 1017 1031 17668192
   PubMed Web of Science ®Google Scholar
• Megger DA Bracht T Meyer HE Sitek B Label-free quantification in clinical proteomics Biochim Biophys Acta 2013 1834 8 1581 1590 23567906
   PubMed Web of Science ®Google Scholar
• Barbi de Moura M Vincent G Fayewicz SL Mitochondrial respiration – an important therapeutic target in melanoma PLoS One 2012 7 8 e40690 22912665
   PubMed Web of Science ®Google Scholar
• Sharma K Vabulas RM Macek B Quantitative proteomics reveals that Hsp90 inhibition preferentially targets kinases and the DNA damage response Mol Cell Proteomics 2012 11 3 M111.014654
   Web of Science ®Google Scholar
• Zhao L Lee BY Brown DA Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling Cancer Res 2009 69 19 7696 7703 19773444
   PubMed Web of Science ®Google Scholar
• Yokoyama T Enomoto T Serada S Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer Int J Cancer 2013 132 2 472 484 22729361
   PubMed Web of Science ®Google Scholar
• Zhang J Nkhata K Shaik AA Mouse prostate proteome changes induced by oral pentagalloylglucose treatment suggest targets for cancer chemoprevention Curr Cancer Drug Targets 2011 11 7 787 798 21762084
   PubMed Web of Science ®Google Scholar
• Dillon R Nilsson CL Shi SD Lee NV Krastins B Greig MJ Discovery of a novel B-Raf fusion protein related to c-Met drug resistance J Proteome Res 2011 10 11 5084 5094 21936566
   PubMed Web of Science ®Google Scholar
• Altelaar AF Munoz J Heck AJ Next-generation proteomics: towards an integrative view of proteome dynamics Nat Rev Genet 2013 14 1 35 48 23207911
   PubMed Web of Science ®Google Scholar
• Nesvizhskii Al Vitek O Aebersold R Analysis and validation of proteomic data generated by tandem mass spectrometry Nat Methods 2007 4 10 787 797 17901868
   PubMed Web of Science ®Google Scholar
• Phillips KA Van Bebber S Issa AM Diagnostics and biomarker development: priming the pipeline Nat Rev Drug Discov 2006 5 6 463 469 16718275
   PubMed Web of Science ®Google Scholar
• Hoskins JM Carey LA McLeod HL CYP2D6 and tamoxifen: DNA matters in breast cancer Nat Rev Cancer 2009 9 8 576 586 19629072
   PubMed Web of Science ®Google Scholar
• Wheeler DL Dunn EF Harari PM Understanding resistance to EGFR inhibitors-impact on future treatment strategies Nat Rev Clin Oncol 2010 7 9 493 507 20551942
   PubMed Web of Science ®Google Scholar
• Al-Ejeh F Smart CE Morrison BJ Breast cancer stem cells: treatment resistance and therapeutic opportunities Carcinogenesis 2011 32 5 650 658 21310941
   PubMed Web of Science ®Google Scholar
• Gangemi R Paleari L Orengo AM Cancer stem cells: a new paradigm for understanding tumor growth and progression and drug resistance Curr Med Chem 2009 16 14 1688 1703 19442140
   PubMed Web of Science ®Google Scholar
• Milas L Hittelman WN Cancer stem cells and tumor response to therapy: current problems and future prospects Semin Radiat Oncol 2009 19 2 96 105 19249647
   PubMed Web of Science ®Google Scholar
• Frame FM Maitland NJ Cancer stem cells, models of study and implications of therapy resistance mechanisms Adv Exp Med Biol 2011 720 105 118 21901622
   PubMed Web of Science ®Google Scholar
• Fodale V Pierobon M Liotta L Petricoin E Mechanism of cell adaptation: when and how do cancer cells develop chemoresistance? Cancer J 2011 17 2 89 95 21427552
   PubMed Web of Science ®Google Scholar
• Thomas H Coley HM Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein Cancer Control 2003 10 2 159 165 12712010
   PubMedGoogle Scholar
• Van Houdt WJ Emmink BL Pham TV Comparative proteomics of colon cancer stem cells and differentiated tumor cells identifies BIRC6 as a potential therapeutic target Mol Cell Proteomics 2011 10 12 M111.11353 21788403
   PubMed Web of Science ®Google Scholar
• Ren F Wu H Lei Y Quantitative proteomics identification of phosphoglycerate mutase 1 as a novel therapeutic target in hepatocellular carcinoma Mol Cancer 2010 9 81 20403181
   PubMed Web of Science ®Google Scholar
• Patel N Chatterjee SK Vrbanac V Rescue of paclitaxel sensitivity by repression of Prohibitin1 in drug-resistant cancer cells Proc Natl Acad Sci U S A 2010 107 6 2503 2508 20133800
   PubMed Web of Science ®Google Scholar
• Tilghman SL Townley I Zhong Q Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness Mol Cell Proteomics 2013 12 9 2440 2455 23704778
   PubMed Web of Science ®Google Scholar
• Zheng S Zhong Q Jiang Q Discovery of a series of thiazole derivatives as novel inhibitors of metastatic cancer cell migration and invasion ACS Med Chem Lett 2013 4 2 191 196 23526571
   PubMed Web of Science ®Google Scholar
• Drewes G Chemical proteomics in drug discovery Methods Mol Biol 2012 803 15 21 22065215
   PubMedGoogle Scholar
• Rix U Superti-Furga G Target profiling of small molecules by chemical proteomics Nat Chem Biol 2009 5 9 616 624 19690537
   PubMed Web of Science ®Google Scholar
• Bantscheff M Scholten A Heck AJ Revealing promiscuous drug-target interactions by chemical proteomics Drug Discov Today 2009 14 21–22 1021 1029 19596079
   PubMed Web of Science ®Google Scholar
• Dadvar P O’Flaherty M Scholten A Rumpel K Heck AJ A chemical proteomics based enrichment technique targeting the interactome of the PDE5 inhibitor PF-4540124 Mol Biosyst 2009 5 5 472 482 19381362
   PubMedGoogle Scholar
• Bantscheff M Eberhard D Abraham Y Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors Nat Biotechnol 2007 25 9 1035 1044 17721511
   PubMed Web of Science ®Google Scholar
• Trinkle-Mulcahy L Boulon S Lam YW Identifying specific protein interaction partners using quantitative mass spectrometry and bead proteomes J Cell Biol 2008 183 2 223 239 18936248
   PubMed Web of Science ®Google Scholar
• Sutton CW The role of targeted chemical proteomics in pharmacology Br J Pharmacol 2012 166 2 457 475 22074351
   PubMed Web of Science ®Google Scholar
• Nomura DK Dix MM Cravatt BF Activity-based protein profiling for biochemical pathway discovery in cancer Nat Rev Cancer 2010 10 9 630 638 20703252
   PubMed Web of Science ®Google Scholar
• Gupta A Raina V Geftinib J Cancer Res Ther 2010 6 3 249 254 21119248
   PubMed Web of Science ®Google Scholar
• Sanford M Scott LJ Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer Drugs 2009 69 16 2303 2328 19852530
   PubMed Web of Science ®Google Scholar
• Ranson M Hammond LA Ferry D ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial J Clin Oncol 2002 20 9 2240 2250 11980995
   PubMed Web of Science ®Google Scholar
• Baselga J Rischin D Ranson M Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types J Clin Oncol 2002 20 21 4292 4302 12409327
   PubMed Web of Science ®Google Scholar
• Gregoire V Hamoir M Chen C Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double-blind, placebo-controlled study Radiother Oncol 2011 100 1 62 69 21821303
   PubMed Web of Science ®Google Scholar
• Perez CA Song H Raez LE Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck Oral Oncol 2012 48 9 887 892 22513208
   PubMed Web of Science ®Google Scholar
• Chen Y Low TY Choong LY Phosphoproteomics identified Endofin, DCBLD2, and KIAA0582 as novel tyrosine phosphorylation targets of EGF signaling and Iressa in human cancer cells Proteomics 2007 7 14 2384 2397 17570516
   PubMed Web of Science ®Google Scholar
• Pernas FG Allen CT Winters ME Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer Clin Cancer Res 2009 15 7 2361 2372 19318490
   PubMed Web of Science ®Google Scholar
• Wu Z Doondeea JB Gholami AM Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer Mol Cell Proteomics 2011 10 12 M111.011635
   Web of Science ®Google Scholar
• Shi H Zhang CJ Chen GY Yao SQ Cell-based proteome profiling of potential dasatinib targets by use of affinity-based probes J Am Chem Soc 2012 134 6 3001 3014 22242683
   PubMed Web of Science ®Google Scholar
• Li J Rix U Fang B A chemical and phosphoproteomic characterization of dasatinib action in lung cancer Nat Chem Biol 2010 6 4 291 299 20190765
   PubMed Web of Science ®Google Scholar
• Winfield LL Payton-Stewart F Celecoxib and Bcl-2: emerging possibilities for anticancer drug design Future Med Chem 2012 4 3 361 383 22393942
   PubMed Web of Science ®Google Scholar
• Kismet K Akay MT Abbasoglu O Ercan A Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention Cancer Detect Prev 2004 28 2 127 142 15068837
   PubMedGoogle Scholar
• Fosslien E Molecular pathology of cyclooxygenase-2 in neoplasia Ann Clin Lab Sci 2000 30 1 3 21 10678579
   PubMed Web of Science ®Google Scholar
• Sareddy GR Geeviman K Ramulu C Babu PP The nonsteroidal anti-inflammatory drug celecoxib suppresses the growth and induces apoptosis of human glioblastoma cells via the NF-κB pathway J Neurooncol 2012 106 1 99 109 21847707
   PubMed Web of Science ®Google Scholar
• Takada Y Bhardwaj A Potdar P Aggarwal BB Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation Oncogene 2004 23 57 9247 9258 15489888
   PubMed Web of Science ®Google Scholar
• Wu T Leng J Han C Demetris AJ The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells Mol Cancer Ther 2004 3 3 299 307 15026550
   PubMed Web of Science ®Google Scholar
• Liu DB Hu GY Long GX Qiu H Mei Q Hu GQ Celecoxib induces apoptosis and cell-cycle arrest in nasopharyngeal carcinoma cell lines via inhibition of STAT3 phosphorylation Acta Pharmacol Sin 2012 33 5 682 690 22504904
   PubMed Web of Science ®Google Scholar
• Lee EJ Kim SH Kwark YE Kim J Heterogeneous nuclear ribonuclear protein C is increased in the celecoxib-induced growth inhibition of human oral squamous cell carcinoma Exp Mol Med 2006 38 3 203 209 16819278
   PubMed Web of Science ®Google Scholar
• Lou J Fatima N Xiao Z Proteomic profiling identifies cyclooxygenase-2-independent global proteomic changes by celecoxib in colorectal cancer cells Cancer Epidemiol Biomarkers Prev 2006 15 9 1598 1606 16985019
   PubMed Web of Science ®Google Scholar
• Polakis P Wnt signaling in cancer Cold Spring Harb Perspect Biol 2012 4 5 pii: a008052
   PubMed Web of Science ®Google Scholar
• Prosperi JR Goss KH A Wnt-ow of opportunity: targeting the Wnt/beta-catenin pathway in breast cancer Curr Drug Targets 2010 11 9 1074 1088 20545611
   PubMed Web of Science ®Google Scholar
• Yao H Ashihara E Maekawa T Targeting the Wnt/β-catenin signaling pathway in human cancers Expert Opin Ther Targets 2011 15 7 873 887 21486121
   PubMed Web of Science ®Google Scholar
• Huang SM Mishina YM Liu S Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling Nature 2009 461 7264 614 620 19759537
   PubMed Web of Science ®Google Scholar
• Seimiya H The telomeric PARP, tankyrases, as targets for cancer therapy Br J Cancer 2006 94 3 341 345 16421589
   PubMed Web of Science ®Google Scholar
• Karlberg T Markova N Johansson I Structural basis for the interaction between tankyrase-2 and a potent Wnt-signaling inhibitor J Med Chem 2010 53 14 5352 5355 20565110
   PubMed Web of Science ®Google Scholar
• Gills JJ Jeffery EH Matusheski NV Moon RC Lantvit DD Pezzuto JM Sulforaphane prevents mouse skin tumorigenesis during the stage of promotion Cancer Lett 2006 236 1 72 79 15993536
   PubMed Web of Science ®Google Scholar
• Myzak MC Dashwood RH Chemoprotection by sulforaphane: keep one eye beyond Keap1 Cancer Lett 2006 233 2 208 218 16520150
   PubMed Web of Science ®Google Scholar
• Fimognari C Hrelia P Sulforaphane as a promising molecule for fighting cancer Mutat Res 2007 635 2–3 90 104 17134937
   PubMed Web of Science ®Google Scholar
• Clarke JD Dashwood RH Ho E Multi-targeted prevention of cancer by sulforaphane Cancer Lett 2008 269 2 291 304 18504070
   PubMed Web of Science ®Google Scholar
• Mastrangelo L Cassidy A Mulholland F Wang W Bao Y Serotonin receptors, novel targets of sulforaphane identified by proteomic analysis in Caco-2 cells Cancer Res 2008 68 13 5487 5491 18593952
   PubMed Web of Science ®Google Scholar
• Lee CH Jeong SJ Yun SM Down-regulation of phosphoglucomutase 3 mediates sulforaphane-induced cell death in LNCaP prostate cancer cells Proteome Sci 2010 8 67 21159204
   PubMed Web of Science ®Google Scholar
• Borrebaeck CA Viewpoints in clinical proteomics: when will proteomics deliver clinically useful information? Proteomics Clin Appl 2012 6 7–8 343 345 22696166
   PubMed Web of Science ®Google Scholar
• Boschetti E Chung MC Righetti PG “The quest for biomarkers”: are we on the right technical track? Proteomics Clin Appl 2012 6 1–2 22 41 22213582
   PubMed Web of Science ®Google Scholar
• Dasilva N Díez P Matarraz S Biomarker discovery by novel sensors based on nanoproteomics approaches Sensors (Basel) 2012 12 2 2284 2308 22438764
   PubMed Web of Science ®Google Scholar
• Dubois E Fertin M Burdese J Amouyel P Bauters C Pinet F Cardiovascular proteomics: translational studies to develop novel biomarkers in heart failure and left ventricular remodeling Proteomics Clin Appl 2011 5 1–2 57 66 21246740
   PubMed Web of Science ®Google Scholar
• Geho DH Petricoin EF Liotta LA Blasting into the microworld of tissue proteomics: a new window on cancer Clin Cancer Res 2004 10 3 825 827 14871957
   PubMed Web of Science ®Google Scholar
• Rho JH Roehrl MH Wang JY Tissue proteomics reveals differential and compartment-specific expression of the homologs transgelin and transgelin-2 in lung adenocarcinoma and its stroma J Proteome Res 2009 8 12 5610 5618 19848416
   PubMed Web of Science ®Google Scholar
• Lehtiö J De Petris L Lung cancer proteomics, clinical and technological considerations J Proteomics 2010 73 10 1851 1863 20685322
   PubMed Web of Science ®Google Scholar
• Peng XC Gong FM Zhao YW Comparative proteomic approach identifies PKM2 and cofilin-1 as potential diagnostic, prognostic and therapeutic targets for pulmonary adenocarcinoma PLoS One 2011 6 11 e27309 22087286
   PubMed Web of Science ®Google Scholar
• Carretero J Shimamura T Rikova K Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors Cancer Cell 2010 17 6 547 559 20541700
   PubMed Web of Science ®Google Scholar
• Tian T Hao J Xu A Determination of metastasis-associated proteins in non-small cell lung cancer by comparative proteomic analysis Cancer Sci 2007 98 8 1265 1274 17537172
   PubMed Web of Science ®Google Scholar
• Yao H Zhang Z Xiao Z Identification of metastasis associated proteins in human lung squamous carcinoma using two-dimensional difference gel electrophoresis and laser capture microdissection Lung Cancer 2009 65 1 41 48 19058872
   PubMed Web of Science ®Google Scholar
• Vander Heiden MG Christofk HR Schuman E Identification of small molecule inhibitors of pyruvate kinase M2 Biochem Pharmacol 2010 79 8 1118 1124 20005212
   PubMed Web of Science ®Google Scholar
• Eiseler T Döppler H Yan IK Kitatani K Mizuno K Storz P Protein kinase D1 regulates cofilin-mediated F-actin reorganization and cell motility through slingshot Nat Cell Biol 2009 11 5 545 556 19329994
   PubMed Web of Science ®Google Scholar
• Nakashima S Matsuda H Kurume A Cucurbitacin E as a new inhibitor of cofilin phosphorylation in human leukemia U937 cells Bioorg Med Chem Lett 2010 20 9 2994 2997 20347305
   PubMed Web of Science ®Google Scholar
• Goo YA Goodlett DR Advances in proteomic prostate cancer biomarker discovery J Proteomics 2010 73 10 1839 1850 20398807
   PubMed Web of Science ®Google Scholar
• Larkin SE Zeidan B Taylor MG Proteomics in prostate cancer biomarker discovery Expert Rev Proteomics 2010 7 1 93 102 20121479
   PubMed Web of Science ®Google Scholar
• Ummanni R Mundt F Pospisil H Identification of clinically relevant protein targets in prostate cancer with 2D-DIGE coupled mass spectrometry and systems biology network platform PLoS One 2011 6 2 e16833 21347291
   PubMed Web of Science ®Google Scholar
• Azimzadeh O Barjaktarovic Z Aubele M Formalin-fixed paraffin-embedded (FFPE) proteome analysis using gel-free and gel-based proteomics J Proteome Res 2010 9 9 4710 4720 20604508
   PubMed Web of Science ®Google Scholar
• Tanca A Pagnozzi D Addis MF Setting proteins free: progresses and achievements in proteomics of formalin-fixed, paraffin-embedded tissues Proteomics Clin Appl 2012 6 1–2 7 21 22213597
   PubMed Web of Science ®Google Scholar
• Ralton LD Murray GI The use of formalin fixed wax embedded tissue for proteomic analysis J Clin Pathol 2011 64 4 297 302 21285242
   PubMed Web of Science ®Google Scholar
• Hara A Sakai N Yamada H Yoshimi N Tanaka T Mori H Immunoblot analysis of the placental form of glutathione S-transferase in protein extracted from paraffin-embedded human glioma tissue J Cancer Res Clin Oncol 1993 119 8 493 496 8509440
   PubMed Web of Science ®Google Scholar
• Layfield R Bailey K Dineen R Application of formalin fixation to the purification of amyloid proteins Anal Biochem 1997 253 1 142 144 9356158
   PubMed Web of Science ®Google Scholar
• Layfield R Bailey K Lowe J Allibone R Mayer RJ Landon M Extraction and protein sequencing of immunoglobulin light chain from formalin-fixed cerebrovascular amyloid deposits J Pathol 1996 180 4 455 459 9014869
   PubMed Web of Science ®Google Scholar
• Shi SR Liu C Balgley BM Lee C Taylor CR Protein extraction from formalin-fixed, paraffin-embedded tissue sections: quality evaluation by mass spectrometry J Histochem Cytochem 2006 54 6 739 743 16399996
   PubMed Web of Science ®Google Scholar
• Shi SR Shi Y Taylor CR Antigen retrieval immunohistochemistry: review and future prospects in research and diagnosis over two decades J Histochem Cytochem 2011 59 1 13 32 21339172
   PubMed Web of Science ®Google Scholar
• Chu WS Liang Q Liu J A nondestructive molecule extraction method allowing morphological and molecular analyses using a single tissue section Lab Invest 2005 85 11 1416 1428 16127423
   PubMed Web of Science ®Google Scholar
• Sprung RW Brock JW Tanksley JP Equivalence of protein inventories obtained from formalin-fixed paraffin-embedded and frozen tissue in multidimensional liquid chromatography-tandem mass spectrometry shotgun proteomic analysis Mol Cell Proteomics 2009 8 8 1988 1998 19467989
   PubMed Web of Science ®Google Scholar
• Ikeda K Monden T Kanoh T Extraction and analysis of diagnostically useful proteins from formalin-fixed, paraffin-embedded tissue sections J Histochem Cytochem 1998 46 3 397 403 9487122
   PubMed Web of Science ®Google Scholar
• Prieto DA Hood BL Darfler MM Liquid tissue: proteomic profiling of formalin-fixed tissues Biotechniques 2005 Suppl:32 35 16528915
   PubMedGoogle Scholar
• Palmer-Toy DE Krastins B Sarracino DA Nadol JBJr Merchant SN Efficient method for the proteomic analysis of fixed and embedded tissues J Proteome Res 2005 4 6 2404 2411 16335994
   PubMed Web of Science ®Google Scholar
• Crockett DK Lin Z Vaughn CP Lim MS Elenitoba-Johnson KS Identification of proteins from formalin-fixed paraffin-embedded cells by LC-MS/MS Lab Invest 2005 85 11 1405 1415 16155593
   PubMed Web of Science ®Google Scholar
• Hwang SI Thumar J Lundgren DH Direct cancer tissue proteomics: a method to identify candidate cancer biomarkers from formalin-fixed paraffin-embedded archival tissues Oncogene 2007 26 1 65 76 16799640
   PubMed Web of Science ®Google Scholar
• Rahimi F Shepherd CE Halliday GM Geczy CL Raftery MJ Antigen-epitope retrieval to facilitate proteomic analysis of formalin-fixed archival brain tissue Anal Chem 2006 78 20 7216 7221 17037924
   PubMed Web of Science ®Google Scholar
• Knight WA Livingston RB Gregory EJ McGuire WL Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer Cancer Res 1977 37 12 4669 4671 922747
   PubMed Web of Science ®Google Scholar
• Mason BH Holdaway IM Mullins PR Yee LH Kay RG Progesterone and estrogen receptors as prognostic variables in breast cancer Cancer Res 1983 43 6 2985 2990 6850609
   PubMed Web of Science ®Google Scholar
• Chevallier B Heintzmann F Mosseri V Prognostic value of estrogen and progesterone receptors in operable breast cancer. Results of a univariate and multivariate analysis Cancer 1988 62 12 2517 2524 3191451
   PubMed Web of Science ®Google Scholar
• Henry JA Nicholson S Farndon JR Westley BR May FE Measurement of oestrogen receptor mRNA levels in human breast tumours Br J Cancer 1988 58 5 600 605 2851309
   PubMed Web of Science ®Google Scholar
• Rezaul K Thumar JK Lundgren DH Differential protein expression profiles in estrogen receptor-positive and -negative breast cancer tissues using label-free quantitative proteomics Genes Cancer 2010 1 3 251 271 21779449
   PubMedGoogle Scholar
• Cabezón T Gromova I Gromov P Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer Mol Cell Proteomics 2013 12 2 381 394 23172894
   PubMed Web of Science ®Google Scholar